Mesa Laboratories, Inc. provided impairment guidance for the fourth quarter of 2024. The company expects that unaudited results for the fourth quarter of 2024 will include non-cash impairment losses of approximately $123 million related to goodwill, of which approximately $98 million relates to the Clinical Genomics division and approximately $25 million relates to the Biopharmaceutical Development division. In addition, The company expects to record non-cash impairment losses to other intangible assets of approximately $148 million, of which $114 million relates to Clinical Genomics division and $34 million relates to Biopharmaceutical Development division.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
116 USD | -0.91% | +0.47% | +10.76% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.76% | 626M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.35% | 40.7B | |
+24.51% | 32.25B | |
+3.43% | 26.53B | |
+14.52% | 25.02B |
- Stock Market
- Equities
- MLAB Stock
- News Mesa Laboratories, Inc.
- Mesa Laboratories, Inc. Provides Impairment Guidance for the Fourth Quarter of 2024